One study posited that a GHK-Cu possibly reduces visible bioindicators, improving skin laxity and clarity
It corroborates, and provides a mechanistic basis for, the previous observations that obesity is associated with a reduced efficacy of incretin hormones in humans, independently of glucose tolerance [5]
Interested in learning if it's right for you
PloS one 10 (11), e0143316
Because GHK-Cu operates through cumulative signaling rather than peak concentration, researchers commonly build in an escalation: a lower dose in the first half of a cycle, a higher dose in the second half, followed by a deliberate rest period before starting again
Its distinction lies not in one striking feature, but in its engineered approach to engage multiple metabolic systems simultaneously